Ask AI
ProCE Banner Activity

PROTAC ER Degraders in ER-Positive/HER2-Negative MBC Progressing After Endocrine Therapy: Latest Updates From SABCS 2025

Clinical Thought

Read this commentary for a brief overview of emerging data and recent clinical trial updates for PROTAC ER degraders in patients with ER-positive/HER2-negative metastatic breast cancer, with data presented at the 2025 San Antonio Breast Cancer Symposium.

Released: February 20, 2026

Continue Activity View Activity

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

Supported by an educational grant from Pfizer, Inc. and Arvinas.

Arvinas

Pfizer, Inc.

Target Audience

This activity is intended for medical oncologists and other healthcare professionals caring for patients with breast cancer.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Explain the current unmet needs in ER+/HER2- mBC and the role of biomarker testing, including ESR1 mutations.

  • Differentiate the mechanisms of action between PROTAC ER degraders and other endocrine therapies.

  • Evaluate current and emerging clinical datap supporting the use of PROTAC ER degraders in patients with endocrine-resistant ER+/HER2- mBC.

Disclosure

Primary Author

Adrienne G. Waks, MD: researcher (paid to institution): Genentech, Gilead, MacroGenics, Merck, TerSera; consultant/advisor/speaker: Ambrx, AstraZeneca, Genentech, Johnson & Johnson.